ROHTAK: The condition of Haryana Health Minister Anil Vij, who is receiving treatment for COVID-19 at Medanta Hospital in Gurugram, is stable and his vital parameters are normal, said Dr. AK Dubey, Medical Superintendent of the hospital. “The Haryana Minister of Health is receiving treatment in the intensive care unit …
Read More »
Hyderabad-based Bharat Biotech on Wednesday released the results of phase 1 trials of its coronavirus (Covid-19) vaccine ‘Covaxin’, which produced a robust immune response against the disease and showed that most of the adverse events were mild and resolved. The vaccine is stored between 2 and 8 degrees Celsius and …
Read More »
NEW DELHI: India will have to spend between $ 1.4 billion and $ 1.8 billion on the first phase of a coronavirus vaccination program, even after receiving support under the global Covax vaccine exchange scheme, according to estimates by the GAVI vaccine alliance. India, which has the world’s second-highest number …
Read More »
HYDERABAD: India’s first indigenous vaccine, Covaxin, managed to induce a robust immune response without any serious adverse events during phase 1 trials that were conducted on 375 volunteers, Bharat Biotech said in a research article. The company said that most of the adverse events seen during the study were mild …
Read More »
Covaxin is a candidate for an indigenously developed coronavirus vaccine (archive) New Delhi: Covaxin, which is one of three coronavirus vaccine candidates being considered for emergency use authorization in India, induced an immune response and did not record any serious adverse events, the company said Wednesday night when publishing the …
Read More »
The Center expects a “good decision” on the Covid-19 vaccine soon and has asked states to identify at least one adverse event management center in each block to monitor the safety and efficacy aspects of the jabs. “When we undertake a universal immunization program, we see some adverse effects in …
Read More »
With safety and efficacy data, Covaxin will be available in the first quarter of 2020, he said. (Archive) Hyderabad: Covaxin, a vaccine for COVID-19, will be available in the first quarter of next year, said Suchitra Ella, joint managing director of Bharat Biotech on Wednesday. “With the safety and efficacy …
Read More »
No emergency use authorization has been granted to the Serum Institute of India (SII) or Bharat Biotech’s COVID-19 vaccines for lack of data, sources told News18 on Wednesday. Bharat Biotech had on Monday applied to the Controller General of Drugs of India (DCGI) for an emergency use authorization for COVID-19 …
Read More »
The panel reviewed the applications of Pfizer, Serum Institute and Bharat Biotech (Representational) New Delhi: Proposals from the Serum Institute and Bharat Biotech for the use of emergency vaccines have not been approved because of inadequate safety and efficacy data, sources said Wednesday. “Both proposals are not approved due to …
Read More »
More than 60 heads of foreign missions who traveled to Hyderabad on Wednesday to visit two biotech companies working on Covid-19 vaccines were briefed by Bharat Biotech President Krishna Ella about the development of Covaxin. During her presentation to high-level diplomats, Ella noted that the medical industry is working to …
Read More »